NYSEAMERICAN:CRMD - Cormedix Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.1741 -0.02 (-10.30 %)
(As of 05/23/2018 08:23 AM ET)
Previous Close$0.19
Today's Range$0.1721 - $0.1940
52-Week Range$0.17 - $0.77
Volume898,399 shs
Average Volume1.41 million shs
Market Capitalization$18.50 million
P/E RatioN/A
Dividend YieldN/A
Beta0.6

About Cormedix (NYSEAMERICAN:CRMD)

Cormedix logoCorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.

Receive CRMD News and Ratings via Email

Sign-up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:CRMD
CUSIPN/A
Phone+1-908-5179500

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-16,300.49%
Return on Equity-318.95%
Return on Assets-227.65%

Miscellaneous

EmployeesN/A
Outstanding Shares81,900,000

Cormedix (NYSEAMERICAN:CRMD) Frequently Asked Questions

What is Cormedix's stock symbol?

Cormedix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CRMD."

How were Cormedix's earnings last quarter?

Cormedix (NYSEAMERICAN:CRMD) announced its quarterly earnings data on Monday, March, 19th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter. The biotechnology company earned $0.09 million during the quarter. Cormedix had a negative return on equity of 318.95% and a negative net margin of 16,300.49%. View Cormedix's Earnings History.

When is Cormedix's next earnings date?

Cormedix is scheduled to release their next quarterly earnings announcement on Wednesday, May, 23rd 2018. View Earnings Estimates for Cormedix.

What price target have analysts set for CRMD?

2 brokerages have issued 1 year price targets for Cormedix's stock. Their predictions range from $3.00 to $4.00. On average, they expect Cormedix's stock price to reach $3.50 in the next year. View Analyst Ratings for Cormedix.

Are investors shorting Cormedix?

Cormedix saw a increase in short interest during the month of April. As of April 30th, there was short interest totalling 6,762,370 shares, an increase of 2.2% from the April 13th total of 6,619,276 shares. Based on an average daily volume of 623,608 shares, the days-to-cover ratio is presently 10.8 days. Currently, 8.8% of the shares of the stock are short sold.

Who are some of Cormedix's key competitors?

Who are Cormedix's key executives?

Cormedix's management team includes the folowing people:
  • Mr. Khoso Baluch, CEO & Director (Age 60)
  • Mr. Robert W. Cook, Chief Financial Officer (Age 62)
  • Mr. John L. Armstrong Jr., MBA, Head of HR & Exec. VP of Technical Operations (Age 74)
  • Ms. Elizabeth Masson, Exec. VP & Head of Clinical Operations
  • Mr. John Ortiz, VP of Regulatory Affairs & Quality Assurance

Has Cormedix been receiving favorable news coverage?

Media coverage about CRMD stock has trended positive recently, according to Accern Sentiment. The research group identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cormedix earned a news impact score of 0.37 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 47.47 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of Cormedix?

Shares of CRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cormedix's stock price today?

One share of CRMD stock can currently be purchased for approximately $0.17.

How big of a company is Cormedix?

Cormedix has a market capitalization of $18.50 million.

How can I contact Cormedix?

Cormedix's mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company can be reached via phone at +1-908-5179500.


MarketBeat Community Rating for Cormedix (CRMD)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  152 (Vote Outperform)
Underperform Votes:  157 (Vote Underperform)
Total Votes:  309
MarketBeat's community ratings are surveys of what our community members think about Cormedix and other stocks. Vote "Outperform" if you believe CRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cormedix (NYSEAMERICAN:CRMD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Cormedix in the last 12 months. Their average twelve-month price target is $2.50, suggesting that the stock has a possible upside of 1,335.96%. The high price target for CRMD is $3.00 and the low price target for CRMD is $2.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.50$3.50$3.6667$3.6667
Price Target Upside: 1,335.96% upside1,844.44% upside474.53% upside474.53% upside

Cormedix (NYSEAMERICAN:CRMD) Consensus Price Target History

Price Target History for Cormedix (NYSEAMERICAN:CRMD)

Cormedix (NYSEAMERICAN:CRMD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
5/23/2018HC WainwrightLower Price TargetBuy ➝ Buy$4.00 ➝ $2.00View Rating Details
8/10/2017Rodman & RenshawLower Price TargetBuy ➝ Buy$5.00 ➝ $3.00View Rating Details
4/24/2017FBR & CoReiterated RatingBuyView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Cormedix (NYSEAMERICAN:CRMD) Earnings History and Estimates Chart

Earnings by Quarter for Cormedix (NYSEAMERICAN:CRMD)

Cormedix (NYSEAMERICAN CRMD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/23/2018        
3/19/2018Q4 2017($0.15)$0.09 millionViewN/AView Earnings Details
11/9/2017Q3 2017($0.14)$0.06 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.16)($0.14)$0.15 million$0.14 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.15)($0.19)$0.09 million$0.04 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.22)($0.16)$0.06 million$0.12 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.15)($0.23)$0.05 million$0.04 millionViewN/AView Earnings Details
8/5/2016Q216($0.11)($0.13)$119.97 million$16.51 millionViewN/AView Earnings Details
5/10/2016Q1($0.09)($0.12)$0.11 million$0.04 millionViewN/AView Earnings Details
3/16/2016Q4 2015($0.16)($0.11)$0.07 million$0.02 millionViewN/AView Earnings Details
11/12/2015Q3($0.13)($0.14)$0.12 million$0.04 millionViewListenView Earnings Details
8/6/2015Q2 2015($0.13)($0.13)$0.08 million$0.12 millionViewN/AView Earnings Details
5/7/2015Q1 2015($0.10)($0.23)$0.07 million$0.03 millionViewN/AView Earnings Details
3/12/2015Q4 2014($0.12)($0.09)$0.08 million$0.09 millionViewN/AView Earnings Details
11/13/2014Q3 2014($0.09)($0.09)$0.08 million$0.05 millionViewN/AView Earnings Details
8/14/2014Q2 2014($0.13)($0.26)$0.02 million$0.04 millionViewN/AView Earnings Details
5/15/2014Q1 2014($0.16)$0.01 millionViewN/AView Earnings Details
3/31/2014Q4 2013($0.22)ViewN/AView Earnings Details
11/19/2013Q3 2013($0.18)ViewN/AView Earnings Details
8/14/2013Q2 2013($0.15)ViewN/AView Earnings Details
5/14/2013Q1 2013($0.10)ViewN/AView Earnings Details
3/27/2013Q4 2012($0.10)ViewN/AView Earnings Details
11/13/2012Q3 2012($0.06)ViewN/AView Earnings Details
8/13/2012Q2 2012($0.05)ViewN/AView Earnings Details
5/15/2012Q1 2012($0.08)ViewN/AView Earnings Details
3/19/2012Q4 2011$0.03ViewN/AView Earnings Details
11/10/2011Q3 2011($0.23)ViewN/AView Earnings Details
8/9/2011Q2 2011($0.20)($0.22)ViewN/AView Earnings Details
5/10/2011Q1 2011($0.13)($0.17)ViewN/AView Earnings Details
3/11/2011Q4 2010($0.09)($0.05)ViewN/AView Earnings Details
11/9/2010Q3 2010($0.18)($0.12)ViewN/AView Earnings Details
8/12/2010Q2 2010($0.18)($0.10)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Cormedix (NYSEAMERICAN:CRMD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Cormedix (NYSEAMERICAN CRMD) Insider Trading and Institutional Ownership History

Insider Trading History for Cormedix (NYSEAMERICAN:CRMD)
Institutional Ownership by Quarter for Cormedix (NYSEAMERICAN:CRMD)

Cormedix (NYSEAMERICAN CRMD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/12/2017Jr. John L ArmstrongVPBuy20,833$0.48$9,999.8420,833View SEC Filing  
12/12/2017Khoso BaluchCEOBuy104,166$0.48$49,999.68225,373View SEC Filing  
12/12/2017Robert W CookCFOBuy52,083$0.48$24,999.84102,083View SEC Filing  
12/12/2017Steven W LefkowitzDirectorBuy135,416$0.48$64,999.68View SEC Filing  
8/18/2017Khoso BaluchCEOBuy36,207$0.42$15,206.94121,207View SEC Filing  
8/18/2017Mehmood KhanDirectorBuy400,000$0.39$156,000.0050,000View SEC Filing  
8/17/2017Myron KaplanDirectorBuy80,000$0.40$32,000.00180,000View SEC Filing  
8/14/2017Myron KaplanDirectorBuy50,000$0.35$17,500.00100,000View SEC Filing  
5/30/2017Cora M TellezDirectorBuy7,550$0.42$3,171.00182,371View SEC Filing  
5/17/2017Khoso BaluchCEOBuy75,000$0.48$36,000.0085,000View SEC Filing  
5/16/2017Cora M TellezDirectorBuy50,000$0.48$24,000.00174,821View SEC Filing  
5/15/2017Janet DillioneDirectorBuy21,231$0.48$10,190.8839,969View SEC Filing  
5/15/2017Robert W CookCFOBuy50,000$0.50$25,000.0050,000View SEC Filing  
5/1/2017Cora M TellezDirectorBuy4,800$0.66$3,168.00124,821View SEC Filing  
3/30/2017Cora M TellezDirectorBuy1,950$1.66$3,237.00120,021View SEC Filing  
2/28/2017Cora M TellezDirectorBuy1,540$2.10$3,234.00118,071View SEC Filing  
2/7/2017Antony PfaffleInsiderSell10,000$2.00$20,000.0010,000View SEC Filing  
1/30/2017Cora M TellezDirectorBuy1,780$1.79$3,186.20116,531View SEC Filing  
12/30/2016Cora M TellezDirectorBuy1,990$1.58$3,144.20114,751View SEC Filing  
12/9/2016Khoso BaluchCEOBuy10,000$1.77$17,700.0010,000View SEC Filing  
11/30/2016Cora M TellezDirectorBuy1,800$1.80$3,240.00112,761View SEC Filing  
10/31/2016Cora M TellezDirectorBuy1,475$2.15$3,171.25110,961View SEC Filing  
10/21/2016Antony PfaffleInsiderSell20,000$2.23$44,600.0020,000View SEC Filing  
9/22/2016Janet DillioneDirectorBuy15,000$2.66$39,900.0015,000View SEC Filing  
8/25/2016Taunia MarkvickaDirectorBuy18,600$1.65$30,690.0022,600View SEC Filing  
8/19/2016Cora M TellezDirectorBuy12,500$1.73$21,625.00109,486View SEC Filing  
6/21/2016Antony PfaffleInsiderSell29,657$2.14$63,465.9810,000View SEC Filing  
6/20/2016Antony PfaffleInsiderSell10,000$2.16$21,600.0010,000View SEC Filing  
6/15/2016Antony PfaffleInsiderSell4,900$2.21$10,829.004,900View SEC Filing  
6/13/2016Antony PfaffleInsiderSell5,443$2.27$12,355.615,000View SEC Filing  
6/9/2016Antony PfaffleInsiderSell10,000$2.38$23,800.0010,000View SEC Filing  
6/8/2016Janet DillioneDirectorBuy3,738$2.67$9,980.4618,738View SEC Filing  
6/3/2016Matthew DuffyDirectorSell46,106$2.73$125,869.3828,571View SEC Filing  
5/31/2016Steven W LefkowitzDirectorSell50,000$2.88$144,000.00159,599View SEC Filing  
5/25/2016Cora M TellezDirectorBuy8,600$2.90$24,940.0096,986View SEC Filing  
5/24/2016Antony PfaffleInsiderSell12,700$2.73$34,671.0012,700View SEC Filing  
5/24/2016Antony PfaffleInsiderSell12,700$2.73$34,671.0012,700View SEC Filing  
5/23/2016Antony PfaffleInsiderSell15,000$2.89$43,350.0010,000View SEC Filing  
5/23/2016Steven W LefkowitzDirectorSell30,000$2.93$87,900.00132,525View SEC Filing  
5/19/2016Antony PfaffleInsiderSell12,300$2.82$34,686.0012,300View SEC Filing  
5/16/2016Antony PfaffleInsiderSell60,000$2.68$160,800.0060,000View SEC Filing  
6/30/2015Randy MilbyCEOBuy1,610$3.88$6,246.80View SEC Filing  
6/23/2015Taunia MarkvickaDirectorBuy4,000$4.81$19,240.00View SEC Filing  
6/15/2015Randy MilbyCEOBuy1,245$5.02$6,249.90View SEC Filing  
6/4/2015Matthew DuffyDirectorSell30,000$6.48$194,400.00View SEC Filing  
5/29/2015Randy MilbyCEOBuy1,026$6.09$6,248.34View SEC Filing  
2/27/2015Randy MilbyCEOBuy1,211$5.16$6,248.76View SEC Filing  
2/13/2015Randy MilbyCEOBuy1,911$3.27$6,248.97View SEC Filing  
1/30/2015Randy MilbyCEOBuy2,016$3.10$6,249.60View SEC Filing  
12/15/2014Randy MilbyCEOBuy4,734$1.32$6,248.88View SEC Filing  
11/28/2014Randy MilbyCEOBuy4,464$1.40$6,249.60View SEC Filing  
11/14/2014Cora M TellezDirectorBuy11,086$1.52$16,850.72View SEC Filing  
11/14/2014Randy MilbyCEOBuy4,111$1.52$6,248.72View SEC Filing  
10/31/2014Randy MilbyCEOBuy3,434$1.82$6,249.88View SEC Filing  
9/30/2014Randy MilbyCEOBuy3,324$1.88$6,249.12View SEC Filing  
9/15/2014Randy MilbyCEOBuy3,654$1.71$6,248.34View SEC Filing  
8/29/2014Randy MilbyCEOBuy3,125$2.00$6,250.00View SEC Filing  
8/15/2014Randy MilbyCEOBuy3,140$1.99$6,248.60View SEC Filing  
7/31/2014Randy MilbyCEOBuy6,250$2.00$12,500.00View SEC Filing  
6/30/2014Randy MilbyCEOBuy2,732$1.83$4,999.56View SEC Filing  
12/13/2013Steven W LefkowitzInsiderBuy18,000$0.78$14,040.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cormedix (NYSEAMERICAN CRMD) News Headlines

Source:
DateHeadline
CorMedixs (CRMD) CEO Khoso Baluch on Q1 2018 Results - Earnings Call TranscriptCorMedix's (CRMD) CEO Khoso Baluch on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 16 at 8:13 AM
Cormedix Inc. Reports First Quarter Financial Results and Provides Business UpdateCormedix Inc. Reports First Quarter Financial Results and Provides Business Update
finance.yahoo.com - May 15 at 5:52 PM
Cormedix (CRMD) Short Interest UpdateCormedix (CRMD) Short Interest Update
www.americanbankingnews.com - May 9 at 5:49 PM
CorMedix Inc. to Report First Quarter 2018 Financial Results on Tuesday, May 15CorMedix Inc. to Report First Quarter 2018 Financial Results on Tuesday, May 15
finance.yahoo.com - May 9 at 8:13 AM
CorMedix Revises Timeline and Announces Changes to Lock-It-100 Study ManagementCorMedix Revises Timeline and Announces Changes to Lock-It-100 Study Management
finance.yahoo.com - April 27 at 8:25 AM
Cormedix (CRMD) Scheduled to Post Quarterly Earnings on ThursdayCormedix (CRMD) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - April 26 at 2:34 AM
Short Interest in Cormedix (CRMD) Grows By 12.6%Short Interest in Cormedix (CRMD) Grows By 12.6%
www.americanbankingnews.com - April 24 at 6:38 PM
CorMedix Inc. (CRMD) Sees Significant Decrease in Short InterestCorMedix Inc. (CRMD) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - April 11 at 2:27 AM
HC Wainwright Analysts Give CorMedix (CRMD) a $3.00 Price TargetHC Wainwright Analysts Give CorMedix (CRMD) a $3.00 Price Target
www.americanbankingnews.com - April 10 at 11:38 PM
HC Wainwright Analysts Give CorMedix (CRMD) a $4.00 Price TargetHC Wainwright Analysts Give CorMedix (CRMD) a $4.00 Price Target
www.americanbankingnews.com - April 7 at 12:27 PM
Zacks Investment Research Lowers CorMedix (CRMD) to SellZacks Investment Research Lowers CorMedix (CRMD) to Sell
www.americanbankingnews.com - April 4 at 8:32 PM
CorMedix (CRMD) Stock Rating Upgraded by Zacks Investment ResearchCorMedix (CRMD) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 3 at 8:49 PM
CorMedix (CRMD) Downgraded by Zacks Investment Research to HoldCorMedix (CRMD) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - March 29 at 7:58 PM
CorMedix (CRMD) Rating Increased to Buy at Zacks Investment ResearchCorMedix (CRMD) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 27 at 9:44 PM
CorMedix Inc. (CRMD) Sees Large Increase in Short InterestCorMedix Inc. (CRMD) Sees Large Increase in Short Interest
www.americanbankingnews.com - March 26 at 6:52 PM
CorMedix (CRMD) Downgraded by Zacks Investment ResearchCorMedix (CRMD) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 22 at 8:42 PM
Zacks Investment Research Upgrades CorMedix (CRMD) to BuyZacks Investment Research Upgrades CorMedix (CRMD) to Buy
www.americanbankingnews.com - March 21 at 8:22 PM
Biotech Stocks Research Reports Released on CorMedix, Curis, Cyclacel Pharma, and Cymabay Therapeutics - PR Newswire (press release)Biotech Stocks' Research Reports Released on CorMedix, Curis, Cyclacel Pharma, and Cymabay Therapeutics - PR Newswire (press release)
www.prnewswire.com - March 21 at 8:41 AM
Cormedix, Inc.: CorMedix Inc. Makes NYSE American Section 610(b) Public AnnouncementCormedix, Inc.: CorMedix Inc. Makes NYSE American Section 610(b) Public Announcement
www.finanznachrichten.de - March 20 at 5:21 PM
CorMedix Inc. Makes NYSE American Section 610(b) Public AnnouncementCorMedix Inc. Makes NYSE American Section 610(b) Public Announcement
finance.yahoo.com - March 20 at 5:21 PM
Cormedix Inc. Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Business UpdateCormedix Inc. Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Business Update
finance.yahoo.com - March 19 at 5:22 PM
Cormedix, Inc.: CorMedix Inc. to Report Fourth Quarter and Full Year 2017 Financial Results on Monday, March 19Cormedix, Inc.: CorMedix Inc. to Report Fourth Quarter and Full Year 2017 Financial Results on Monday, March 19
www.finanznachrichten.de - March 13 at 7:22 PM
CorMedix Inc. to Report Fourth Quarter and Full Year 2017 Financial Results on Monday, March 19CorMedix Inc. to Report Fourth Quarter and Full Year 2017 Financial Results on Monday, March 19
finance.yahoo.com - March 13 at 8:18 AM
Short Interest in CorMedix Inc. (CRMD) Rises By 5.1%Short Interest in CorMedix Inc. (CRMD) Rises By 5.1%
www.americanbankingnews.com - March 9 at 6:22 PM
CorMedix (CRMD) Set to Announce Earnings on ThursdayCorMedix (CRMD) Set to Announce Earnings on Thursday
www.americanbankingnews.com - March 8 at 1:10 AM
Short Interest in CorMedix Inc. (CRMD) Declines By 0.3%Short Interest in CorMedix Inc. (CRMD) Declines By 0.3%
www.americanbankingnews.com - March 1 at 1:52 AM
CorMedix Inc. Provides Update on Its Financing Plans in Connection with Its Ongoing LOCK-IT 100 Clinical StudyCorMedix Inc. Provides Update on Its Financing Plans in Connection with Its Ongoing LOCK-IT 100 Clinical Study
finance.yahoo.com - February 27 at 5:58 PM
CorMedix Inc. Granted Orphan Drug Designation for Taurolidine for Treatment of NeuroblastomaCorMedix Inc. Granted Orphan Drug Designation for Taurolidine for Treatment of Neuroblastoma
finance.yahoo.com - February 26 at 8:13 AM
Why CorMedix Inc. (CRMD) Shares Took a Nosedive TodayWhy CorMedix Inc. (CRMD) Shares Took a Nosedive Today
finance.yahoo.com - February 20 at 5:50 PM
CorMedix Inc. Achieves Target Number of Events in Its LOCK-IT-100 Study of Neutrolin(R) for Interim Efficacy AnalysisCorMedix Inc. Achieves Target Number of Events in Its LOCK-IT-100 Study of Neutrolin(R) for Interim Efficacy Analysis
finance.yahoo.com - February 20 at 8:13 AM
CorMedix Inc. (CRMD) Short Interest UpdateCorMedix Inc. (CRMD) Short Interest Update
www.americanbankingnews.com - February 9 at 8:28 PM
Technical Perspectives on Biotech Stocks -- CorMedix, Curis, Cyclacel Pharma, and Cymabay TherapeuticsTechnical Perspectives on Biotech Stocks -- CorMedix, Curis, Cyclacel Pharma, and Cymabay Therapeutics
www.bizjournals.com - February 9 at 9:21 AM
CorMedix Inc. (CRMD) Short Interest Up 8.3% in JanuaryCorMedix Inc. (CRMD) Short Interest Up 8.3% in January
www.americanbankingnews.com - January 24 at 6:10 PM
CorMedix Inc. (CRMD) Short Interest Down 10.2% in DecemberCorMedix Inc. (CRMD) Short Interest Down 10.2% in December
www.americanbankingnews.com - January 11 at 2:36 AM
ETFs with exposure to CorMedix, Inc. : January 1, 2018ETFs with exposure to CorMedix, Inc. : January 1, 2018
finance.yahoo.com - January 1 at 5:12 PM
CorMedix, Inc. :CRMD-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017CorMedix, Inc. :CRMD-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 28 at 1:16 PM
Short Interest in CorMedix Inc. (CRMD) Increases By 20.4%Short Interest in CorMedix Inc. (CRMD) Increases By 20.4%
www.americanbankingnews.com - December 27 at 6:38 PM
ETFs with exposure to CorMedix, Inc. : December 19, 2017ETFs with exposure to CorMedix, Inc. : December 19, 2017
finance.yahoo.com - December 19 at 5:16 PM
CorMedix Inc. (CRMD) CFO Robert W. Cook Acquires 52,083 SharesCorMedix Inc. (CRMD) CFO Robert W. Cook Acquires 52,083 Shares
www.americanbankingnews.com - December 14 at 6:50 PM
Khoso Baluch Buys 104,166 Shares of CorMedix Inc. (CRMD) StockKhoso Baluch Buys 104,166 Shares of CorMedix Inc. (CRMD) Stock
www.americanbankingnews.com - December 14 at 6:28 PM
CorMedix Inc. (CRMD) Director Steven W. Lefkowitz Acquires 135,416 SharesCorMedix Inc. (CRMD) Director Steven W. Lefkowitz Acquires 135,416 Shares
www.americanbankingnews.com - December 14 at 6:26 PM
ETFs with exposure to CorMedix, Inc. : December 7, 2017ETFs with exposure to CorMedix, Inc. : December 7, 2017
finance.yahoo.com - December 7 at 5:43 PM
CorMedix Inc. Announces Acceptance of Final Post-Marketing Study Data to be Published in the European Journal of Clinical Microbiology and Infectious DiseasesCorMedix Inc. Announces Acceptance of Final Post-Marketing Study Data to be Published in the European Journal of Clinical Microbiology and Infectious Diseases
finance.yahoo.com - December 5 at 10:14 AM
CorMedix Inc (CRMD): Should The Recent EPS Drop Worry You?CorMedix Inc (CRMD): Should The Recent EPS Drop Worry You?
finance.yahoo.com - December 4 at 5:16 PM
CorMedix Inc. to Host Seminar on Hemodialysis Catheter Complications at 17th Annual Conference on NephrologyCorMedix Inc. to Host Seminar on Hemodialysis Catheter Complications at 17th Annual Conference on Nephrology
finance.yahoo.com - November 29 at 9:37 AM
Short Interest in CorMedix Inc. (CRMD) Grows By 21.6%Short Interest in CorMedix Inc. (CRMD) Grows By 21.6%
www.americanbankingnews.com - November 27 at 7:48 PM
CorMedix Inc. Announces Common Stock Purchase by Company Directors and Executive Management TeamCorMedix Inc. Announces Common Stock Purchase by Company Directors and Executive Management Team
finance.yahoo.com - November 20 at 6:34 PM

SEC Filings

Cormedix (NYSEAMERICAN:CRMD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cormedix (NYSEAMERICAN:CRMD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cormedix (NYSEAMERICAN CRMD) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.